HIGHLIGHTS
SUMMARY
Essential thrombocythemia is a chronic myeloproliferative neoplasm associated with thrombo-hemorrhagic events and the progression to myelofibrosis or acute myeloid leukemia. Leukocytosis at diagnosis was associated with a higher risk of thrombosis, and JAK2V617F-positive cases exhibited a 1.5-fold higher risk of developing thrombotic events. Essential thrombocythemia (ET) is a classical chronic myeloproliferative neoplasm (MPN) which, according to the 2016 World Health Organization (WHO) classification, is associated with a good prognosis and a median survival in patients aged less than 60 years at diagnosis of 33 years. In the aforementioned assessment, individuals . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.